Landos Biopharma Inc expected to post a loss of 44 cents a share - Earnings Preview

Landos Biopharma

12/11/2021 16:30

* Landos Biopharma Inc  LABP.OQ   LABP.O  is expected to report
results on November 15.
​* Refinitiv's mean analyst estimate for Landos Biopharma Inc is
for a loss of 44 cents per share. 
* The current average analyst rating on the shares is "buy" and
the breakdown of recommendations is 6 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell." 
* The mean earnings estimate of analysts was unchanged in the
last three months. ​
* Wall Street's median 12-month price target for Landos
Biopharma Inc is $35​, about 57.2% above​ its last closing price
of $14.99. ​​​
* Previous quarterly performance (using preferred earnings
measure in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Jun. 30 2021  0.04        -0.14      0.12      Beat    185.7
 Mar. 31 2021  -0.39       -0.37      -0.38     Missed  -1.3
 Dec. 31 2020  -0.69       -0.69      -0.91     Missed  -32.5​
 ​​                                                     
                                                        ​
 This summary was machine generated November 12 at 16:30 GMT. 
All figures in US dollars  unless otherwise stated